Tetherex Pharmaceuticals Overview

  • Status
  • Private
  • Employees
  • 6
Employees
  • Latest Deal Type
  • Series B
  • Latest Deal Amount
  • $50M
Latest Deal Amount
  • Investors
  • 7

Tetherex Pharmaceuticals General Information

Description

Developer of a medicinal drugs designed to treat thrombosis, inflammation and tumor metastasis. The company's drugs develop novel first-in-class therapeutics targeting cell adhesion proteins in thrombotic, inflammatory and oncologic diseases to work on the molecular mechanisms of cell adhesion and inflammation, enabling patients who suffer these afflictions enjoy descent and long lives.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Primary Office
  • 840 Research Parkway
  • Suite 516
  • Oklahoma City, OK 73104
  • United States
+1 (405) 000-0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Tetherex Pharmaceuticals Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
11. Later Stage VC (Series B) 07-Mar-2018 $50M 000.00 Completed Clinical Trials - General
10. Debt - General 09-Oct-2015 000 000.00 Completed Clinical Trials - General
9. Seed Round 01-Jul-2015 000 000.00 Completed Clinical Trials - General
8. Later Stage VC (Series A) 09-Feb-2015 00.000 000.00 000.00 Completed Clinical Trials - General
7. Seed Round 30-Oct-2014 000.00 Completed Clinical Trials - General
6. Later Stage VC (Series A) 17-Sep-2012 0000 000.00 000.00 Completed Clinical Trials - General
5. Angel (individual) 01-Apr-2010 0000 00.000 Completed Clinical Trials - General
4. Grant 16-Jun-2009 00.00 00.00 Completed Clinical Trials - General
3. Later Stage VC 16-Jun-2009 $3.5M $3.5M Completed Clinical Trials - General
2. Grant 28-Apr-2009 $300K Completed Clinical Trials - General
To view Tetherex Pharmaceuticals’s complete valuation and funding history, request access »

Tetherex Pharmaceuticals Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate ($) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series B 0,000,000 00.000000 00.0 000 000 00 000 00.000
Series A 0,000,000 00.000000 00.00 00.00 00.00 00 00.00 00.000
To view Tetherex Pharmaceuticals’s complete cap table history, request access »

Tetherex Pharmaceuticals Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of a medicinal drugs designed to treat thrombosis, inflammation and tumor metastasis. The company's drugs deve
Biotechnology
Oklahoma City, OK
6 As of 2012
000.00
00000000000 000.00

00000000

tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitati
0000000000000
Seal Beach, CA
000 As of 0000
00.00
000000000 - 00.00

000 0000

in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occ
0000000000000
Ann Arbor, MI
00 As of 0000
000.00
00000000000 000.00
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Tetherex Pharmaceuticals Competitors (29)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Dendreon Venture Capital-Backed Seal Beach, CA 000 00.00 000000000 - 00.00
000 000000000000 Venture Capital-Backed Ann Arbor, MI 00 000.00 00000000000 000.00
00000000 000000000 Corporation Norcross, GA 0 000000000000
0000 0000 00000000 Formerly VC-backed Cambridge, MA 000 00000 00000000000 00000
000000 00000000000 Corporation Cambridge, MA 000 00000 000000 - 000 00000
You’re viewing 5 of 29 competitors. Get the full list »

Tetherex Pharmaceuticals Executive Team (8)

Name Title Board Seat Contact Info
Scott Rollins Ph.D Chief Executive Officer & Chairman
Russell Rother Ph.D President, Board Member & Chief Operating Officer
Ziad Kawar Ph.D Senior Scientist
Richard Cummings Ph.D Co-Founder
Jonathan Stocker Ph.D Senior Director, Clinical Development
You’re viewing 5 of 8 executive team members. Get the full list »

Tetherex Pharmaceuticals Board Members (5)

Name Representing Role Since
David Keiser Self Board Member 000 0000
Philip Jones MD Self Board Member 000 0000
Rodger McEver MD Tetherex Pharmaceuticals Co-Founder & Board Member 000 0000
Scott Rollins Ph.D Tetherex Pharmaceuticals Chief Executive Officer & Chairman 000 0000
Todd Foley MPM Capital Board Member 000 0000
To view Tetherex Pharmaceuticals’s complete board members history, request access »

Tetherex Pharmaceuticals Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Tetherex Pharmaceuticals Investors (7)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Philip Jones Angel (individual) Minority 000 0000 000000 0
MPM Capital Venture Capital Minority 000 0000 000000 0
RAIN Source Capital Angel Group Minority 000 0000 000000 0
i2E Venture Capital Minority 000 0000 000000 0
Oklahoma Life Science Fund Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 7 investors. Get the full list »